EXAS:NSC-Exact Sciences Corporation

EQUITY | Medical Diagnostics & Research | NASDAQ Capital Market

Last Closing

USD 74.97

Change

-2.12 (-2.75)%

Market Cap

USD 1.60B

Volume

1.33M

Analyst Target

USD 88.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Exact Sciences Corp is a molecular diagnostics company currently focused on the early detection and prevention of colorectal cancer. It has developed a non?invasive, patient friendly screening test called Cologuard(R).

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-16 )

Largest Industry Peers for Medical Diagnostics & Research

ETFs Containing EXAS

CURE:AU ETFS S&P Biotech ETF 1.13 % 0.00 %

-1.09 (0%)

USD 0.04B
ARKG 0.00 % 0.75 %

N/A

N/A
LABS 0.00 % 0.45 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

-6.59 (0%)

USD 1.24B
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

-0.92 (0%)

USD 0.04B
TWOK 0.00 % 0.10 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

-1.80 (0%)

USD 7.05B
NIFE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Diagnostics & Research) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.81% 67% D+ 83% B
Dividend Return N/A N/A N/A N/A F
Total Return 18.81% 67% D+ 83% B
Trailing 12 Months  
Capital Gain 41.59% 80% B- 92% A
Dividend Return N/A N/A N/A N/A F
Total Return 41.59% 80% B- 92% A
Trailing 5 Years  
Capital Gain 415.97% 91% A- 98% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 415.97% 91% A- 97% N/A
Average Annual (5 Year Horizon)  
Capital Gain 79.81% 95% A 97% N/A
Dividend Return 79.81% 95% A 97% N/A
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 118.35% 5% F 5% F
Risk Adjusted Return 67.44% 84% B 72% C
Market Capitalization 1.60B 95% A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Diagnostics & Research) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -63.53 92% 95%
Price/Book Ratio 12.37 15% 7%
Price / Cash Flow Ratio -32.88 100% 98%
Price/Free Cash Flow Ratio -44.89 95% 93%
Management Effectiveness  
Return on Equity -21.43% 52% 29%
Return on Invested Capital -11.87% 53% 35%
Return on Assets -11.79% 56% 30%
Debt to Equity Ratio 63.50% 43% 40%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector